{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:00:01Z","timestamp":1789506001709,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10552-017-0940-9","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T02:52:37Z","timestamp":1504234357000},"page":"1285-1293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of treatment in men with prostate cancer at the cancer centre Bahamas"],"prefix":"10.1007","volume":"28","author":[{"given":"Glenn Wayne","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Kellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevein","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Nottage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine Sin","family":"Quee-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conville","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"940_CR1","first-page":"1395","volume":"65","author":"H Razzaghi","year":"2016","unstructured":"Razzaghi H, Quesnel-Crooks S, Sherman R, Joseph R, Kohler B, Andall-Brereton G, Ivey MA, Edwards BK, Mery L, Gawryszewski V, Saraiya M (2016) Leading causes of cancer mortality\u2014Caribbean Region, 2003-2013. MMWR 65:1395\u20131400","journal-title":"MMWR"},{"key":"940_CR2","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.9778\/cmajo.20140079","volume":"4","author":"J Dickinson","year":"2016","unstructured":"Dickinson J, Shane A, Tonelli M, Gorber SC, Joffres M, SinghH Bell N (2016) Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening. CMAJ open 4:E73. doi: 10.9778\/cmajo.20140079","journal-title":"CMAJ open"},{"key":"940_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5489\/cuaj.2806","volume":"9","author":"C Morash","year":"2015","unstructured":"Morash C, Tey R, Aqbassi C, Klotz L, McGowan T, Srigley J, Evans A (2015) Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 9:171\u2013178","journal-title":"Can Urol Assoc J"},{"key":"940_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.aogh.2014.09.009","volume":"80","author":"MP Curado","year":"2014","unstructured":"Curado MP, de Souza DLB (2014) Cancer burden in Latin America and the Caribbean. Ann Glob Health 80:370\u2013377","journal-title":"Ann Glob Health"},{"key":"940_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.21149\/spm.v58i2.7779","volume":"58","author":"F Bray","year":"2016","unstructured":"Bray F, Pineros M (2016) Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud Publ Mex 58:104\u2013117","journal-title":"Salud Publ Mex"},{"key":"940_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.5114\/jcb.2016.62972","volume":"8","author":"JE Mensah","year":"2016","unstructured":"Mensah JE, Yarney J, Vanderpuye V, Akpakli E, Tagoe S, Sasu E (2016) Prostate brachytherapy in Ghana: our initial experience. J Contemp Brachyther 8:379\u2013385","journal-title":"J Contemp Brachyther"},{"key":"940_CR7","isbn-type":"print","volume-title":"Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan)","author":"R Sankaranarayanan","year":"2011","unstructured":"Sankaranarayanan R, Swaminathan R, Lucas E (2011) Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan), vol 162. International Agency for Research on Cancer (IARC) Scientific Publications, Lyon. ISBN 978-92-832-2162-3","ISBN":"https:\/\/id.crossref.org\/isbn\/9789283221623"},{"key":"940_CR8","unstructured":"Globocan (2012) Estimated cancer incidence, mortality and prevalence worldwide in 2012. www.globocan.iarc.fr"},{"key":"940_CR9","unstructured":"National Comprehensive Cancer Network (2016) Prostate cancer. Version 1.2017. www.NCCN.org . Accessed 16 Dec 2016"},{"key":"940_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1590\/S0043-31442006000100008","volume":"55","author":"C Brown","year":"2006","unstructured":"Brown C, Sin Quee C, Spencer H, Roberts R, Coleman H, Francis B, King C (2006) Partnered care in The Bahamas: a model of advanced healthcare delivery for developing countries. WIMJ 55:30\u201336","journal-title":"WIMJ"},{"key":"940_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5489\/cuaj\/1068","volume":"4","author":"JR Srigley","year":"2010","unstructured":"Srigley JR, Merrimen JL, Jones G, Jamal M (2010) Multifocal high-grade prostatic intra-epithelial neolasia is still a significant risk factor for adenocarcinoma. Can Urol Assoc J 4:434","journal-title":"Can Urol Assoc J"},{"key":"940_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5489\/cuaj.11085","volume":"6","author":"G Rodrigues","year":"2012","unstructured":"Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, Lukka H (2012) Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J 6:121\u2013127","journal-title":"Can Urol Assoc J"},{"key":"940_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/adco.12664","author":"N Tomita","year":"2017","unstructured":"Tomita N, Soga N, Ogura Y, Kageyama T, Kodaira T (2017) Very high-risk prostate cancer: stratification of outcomes of radiotherapy and long-term androgen deprivation therapy. Asia Pac J Clin Oncol. doi: 10.1111\/adco.12664","journal-title":"Asia Pac J Clin Oncol"},{"key":"940_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13014-016-0743-2","volume":"12","author":"A Saad","year":"2017","unstructured":"Saad A, Goldstein J, Lawrence YR, Spieler B, Leibowitz-Amit R, Berger R, Davidson T, Urban D, Tsang L, Alezra D, Weiss I, Symon Z (2017) Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation? Radiat Oncol 12:5","journal-title":"Radiat Oncol"},{"key":"940_CR15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Ecevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Committee Grading (2016) The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostate carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244\u2013252","journal-title":"Am J Surg Pathol"},{"key":"940_CR16","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","volume":"34","author":"RC Chen","year":"2016","unstructured":"Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, Morgan SC, Tyldesley S, Haluschak JJ, Tan W, Justman S, Jain S (2016) Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol 34:2182\u20132190","journal-title":"J Clin Oncol"},{"key":"940_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13862","author":"JM Telang","year":"2017","unstructured":"Telang JM, Lane BR, Cher ML, Miller DC, Dupree JM (2017) Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature. BJU Int. doi: 10.1111\/bju.13862","journal-title":"BJU Int"},{"key":"940_CR18","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1002\/cncr.24348","volume":"115","author":"M Roach","year":"2009","unstructured":"Roach M, Waldman F, Pollack A (2009) Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 115:3112\u20133120","journal-title":"Cancer"},{"key":"940_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijrobp.2010.11.074","volume":"80","author":"LK Morikawa","year":"2011","unstructured":"Morikawa LK, Roach M (2011) Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys 80:6\u201316","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"940_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","volume":"69","author":"C Lawton","year":"2007","unstructured":"Lawton C, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider Rotman, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions. Int J Radiat Oncol Biol Phys 69:646\u2013655","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"940_CR21","volume-title":"Vital statistics","author":"Health Information and Research Unit","year":"2014","unstructured":"Health Information and Research Unit (2014) Vital statistics. Department of Statistics, The Bahamas"},{"key":"940_CR22","unstructured":"Health Information and Research Unit (2015) Princess margaret hospital cancer registry. Public Hospital Authority"},{"key":"940_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pros.2990170409","volume":"17","author":"GD Steinberg","year":"1990","unstructured":"Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. Prostate 17:337\u2013347","journal-title":"Prostate"},{"key":"940_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pros.23247","volume":"77","author":"FS Albright","year":"2017","unstructured":"Albright FS, Stephenson RA, Agarwal N, Cannon-Albright LA (2017) Relative risks for lethal prostate cancer based on complete family history of prostate cancer deaths. Prostate 77:41\u201348","journal-title":"Prostate"},{"key":"940_CR25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10903-012-9710-7","volume":"15","author":"B Nemesure","year":"2013","unstructured":"Nemesure B, Wu SY, Hennis A, Leske MC (2013) Family history of prostate cancer in a black population. J Immigr Minor Health 15:1107\u20131112","journal-title":"J Immigr Minor Health"},{"key":"940_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0090-4295(98)00200-3","volume":"52","author":"FE Glover Jr","year":"1998","unstructured":"Glover FE Jr, Coffey DS, Douglas LL, Russell H, Cadigan M, Tulloch T, Wedderburn K, Wan RL, Baker TD, Walsh PC (1998) Familial study of prostate cancer in Jamaica. Urology 52:441\u2013443","journal-title":"Urology"},{"key":"940_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10552-011-9850-4","volume":"23","author":"MD Jackson","year":"2012","unstructured":"Jackson MD, Walker SP, Simpson-Smith CM, Lindsay CM, Smith G, McFarlane-Anderson N, Bennett FI, Coard KC, Aiken WD, Tulloch T, Paul TJ, Wan RL (2012) Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. Cancer Causes Control 23:23\u201333","journal-title":"Cancer Causes Control"},{"key":"940_CR28","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.urology.2007.02.039","volume":"69","author":"S Mallick","year":"2007","unstructured":"Mallick S, Romana M, Blanchet P, Multigner L (2007) GSTM1 and GSTT1 polymorphisms and the risk of prostate cancer in a Caribbean population of African descent. Urology 69:1165\u20131169","journal-title":"Urology"},{"issue":"9","key":"940_CR29","doi-asserted-by":"publisher","first-page":"e107275","DOI":"10.1371\/journal.pone.0107275","volume":"9","author":"E Emeville","year":"2014","unstructured":"Emeville E, Broquere C, Brureau L, Ferdinand S, Blanchet P, Multigner L, Romana M (2014) Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in the Caribbean population of African descent. PLoS ONE 9(9):e107275. doi: 10.1371\/journal.pone.0107275","journal-title":"PLoS ONE"},{"key":"940_CR30","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO.2009.27.2153","volume":"28","author":"L Multigner","year":"2010","unstructured":"Multigner L, Ndong JR, Giusti A, Romana M, Delacroix-Maillard H, Cordier S, Jegou B, Thome JP, Blanchet P (2010) Chlordecone exposure and risk of prostate cancer. J Clin Oncol 28:3457\u20133462","journal-title":"J Clin Oncol"},{"key":"940_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ijrobp.2016.11.002","volume":"97","author":"AJ Mirhadi","year":"2016","unstructured":"Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM (2016) Effect of long-term hormonal theapy (vs. short-term hormonal therapy): a secondary analysis of intermediate-risk prostate cancer patients treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Phys. 97:511\u2013515","journal-title":"Int J Radiat Oncol Phys."},{"key":"940_CR32","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.ijrobp.2015.07.106","volume":"93","author":"CAF Lawton","year":"2016","unstructured":"Lawton CAF, Dignam JJ, Hanks GE, Lepor H, Grignon D, Bereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatsesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Kwok Y, Roach M, Lin X, Sandler HM (2016) Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology\/RTOG 9202. Int J Radiat Oncol Phys 93:S44","journal-title":"Int J Radiat Oncol Phys"},{"key":"940_CR33","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1002\/cncr.28213","volume":"229","author":"QN Nguyen","year":"2013","unstructured":"Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA (2013) Long-term outcomes for men with high-risk prostate cancer treated definitively with external bean radiotherapy with or without androgen deprivation. Cancer 229:3265\u20133271","journal-title":"Cancer"},{"key":"940_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","volume":"15","author":"DP Dearnaley","year":"2014","unstructured":"Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Aird EG, Bottomley D, Huddart RA, Jose CC, Matthews JHL, Millar JL, Murphy C, Russell JM, Scrase CD, Parmar MKB, Sydes MR (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464\u2013473","journal-title":"Lancet Oncol"},{"key":"940_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/107327481602300406","volume":"23","author":"PS Pinheiro","year":"2016","unstructured":"Pinheiro PS, Callahan KE, Ragin CD, Hage RW, Hylton T, Kobetz EN (2016) Black Heterogeneity in Cancer Mortality: US-Blacks, Haitians and Jamaicans. Cancer Control 23:347\u2013358","journal-title":"Cancer Control"},{"key":"940_CR36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/pros.21144","volume":"70","author":"B Mutetwa","year":"2010","unstructured":"Mutetwa B, Taioli E, Attong-Rogers A, Layne P, Roach V, Ragin C (2010) Prostate cancer characteristics and survival in males of African ancestry according to place of birth: data from Brooklyn-New York, Guyana, Tobago and Trinidad. Prostate 70:1102\u20131109","journal-title":"Prostate"},{"key":"940_CR37","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/pon.4222","volume":"25","author":"C Rivas","year":"2016","unstructured":"Rivas C, Matheson L, Nayoan J, Glaser A, Gavin A, Wright P, Wagland R, Watson E (2016) Ethnicity and the prostate cancer experience: a qualitative metasynthesis. Psychooncology 25:1147\u20131156","journal-title":"Psychooncology"},{"key":"940_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13063-015-0598-0","volume":"16","author":"S MacLennan","year":"2015","unstructured":"MacLennan S, Bekema HJ, Williamson PR, Campbell MK, Stewart F, MacLennan SJ, N\u2019Dow JMO, Lam TBL (2015) A core outcome set for localized prostate cancer effectiveness trials: protocol for a systematic review of the literature and stakeholder involvement through interviews and a Delphi survey. Trials 16:76","journal-title":"Trials"},{"issue":"S1","key":"940_CR39","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1750-9378-4-S1-S2","volume":"4","author":"FT Odedina","year":"2009","unstructured":"Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N (2009) Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 4(S1):S2","journal-title":"Infect Agent Cancer"},{"key":"940_CR40","first-page":"225","volume":"37","author":"C Alberti","year":"2016","unstructured":"Alberti C (2016) Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmogenomic approaches to overcome immunotherapy cancer resistance. G Chir 37:225\u2013235","journal-title":"G Chir"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-017-0940-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-017-0940-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-017-0940-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T01:44:01Z","timestamp":1659404641000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-017-0940-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1007\/s10552-017-0940-9","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,1]]},"assertion":[{"value":"14 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}